Neuphoria Therapeutics
Update in progressNEUP (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on novel allosteric ion channel modulators for CNS disorders. Its lead candidate, BNC210, is a selective negative allosteric modulator of the alpha-7 receptor for social anxiety disorder and is in phase 2b for PTSD. The portfolio includes BNC101 (anti-cancer stem cell–targeting monoclonal antibody) and BNC105 for cancer, plus preclinical programs NextGen and a Kv3.1/3.2 agonist. Formerly Bionomics, renamed in Dec 2024; founded 1996, based in Burlington, MA, with Merck collaboration on A7 PAMs.
Company score
- Sentiment
- -0.48
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.10
- Governance
- -0.40
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.30
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Spyridon Papapetropoulos M.D., Ph.D.
- Founded1996
- Employees7
- Websitewww.neuphoriatx.com
Identifiers
- ISINUS64136E1029
- FIGIBBG01RFZ8658
- CUSIP64136E102
- CIK0001191070